SELLAS Life Sciences Group, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
SELLAS Life Sciences Group, Inc. (SLS) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$20.70 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-31.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2022-03-31
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-12-31 was -$6.60M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-09-30 was -$7.08M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-06-30 was -$4.61M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2021-03-31 was -$2.40M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$20.70M.
- SELLAS Life Sciences Group, Inc. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$16.84M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|
| 2021-12-31 | -$6.60M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$13.68M derived: sum of 2 quarters · filed 2022-03-31 | -$18.30M derived: sum of 3 quarters · filed 2022-03-31 | -$20.70M 10-K · filed 2022-03-31 |
| 2021-09-30 | -$7.08M 10-Q · filed 2021-11-12 | -$11.70M derived: sum of 2 quarters · filed 2021-11-12 | -$14.10M 10-Q · filed 2021-11-12 | -$17.82M derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-06-30 | -$4.61M 10-Q · filed 2021-08-12 | -$7.02M 10-Q · filed 2021-08-12 | -$10.73M derived: sum of 3 quarters · filed 2022-03-31 | -$15.21M derived: sum of 4 quarters · filed 2022-03-31 |
| 2021-03-31 | -$2.40M derived: 10-K 12 month − 3 quarters · filed 2022-03-31 | -$6.12M derived: sum of 2 quarters · filed 2022-03-31 | -$10.59M derived: sum of 3 quarters · filed 2022-03-31 | -$15.02M derived: sum of 4 quarters · filed 2022-03-31 |
| 2020-12-31 | -$3.72M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$8.19M derived: sum of 2 quarters · filed 2022-03-31 | -$12.61M derived: sum of 3 quarters · filed 2022-03-31 | -$16.84M 10-K · filed 2022-03-31 |
| 2020-09-30 | -$4.47M 10-Q · filed 2021-11-12 | -$8.90M derived: sum of 2 quarters · filed 2021-11-12 | -$13.12M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$4.42M 10-Q · filed 2021-08-12 | -$8.65M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |